SH2D3A

Across TCGA pan-cancer cohorts, SH2D3A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH2D3A data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SH2D3A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SH2D3A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and PRAD are the cancer types where SH2D3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.657	0.902	.006	20	view →
UCEC	DFS	Median	All	0.970	0.828	.023	16	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	All	0.147	0.680	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SH2D3A–BRCA (DFS)

Open the BRCA breakdown →